ENTX Entera Bio: Price-to-Projected Revenue Ratio
How can Entera Bio Ltd. (ENTX) attract leading biochemists to develop oral proteins? The forward revenue multiple illustrates the business valuation trend, where 1512.30 shows the current value of the metric. Stability is ensured by independence from GDP cycles and FDA approval, while the environmental footprint is minimized through the safe disposal of laboratory reagents.
Comprehensive metric breakdowns and analytics for enterabio.com (ENTX)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
- net income and valuation multiples indicators:
ENTX - Net Financial Result|Expected Profit Entera Bio Ltd.|ENTX - Market Cap to Earnings|Projected Price to Earnings Entera Bio|ENTX - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ENTX|ENTX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Entera Bio|ENTX - Earnings per share for the last four quarters|Quarterly EPS earnings growth enterabio.com|ENTX - Earnings per share growth this year|Expected earnings per share growth for next year Entera Bio Ltd.
- issuer revenue and sales details:
Fundamental company analysis:Entera Bio Corp (ENTX)
For Entera Bio Ltd. (ENTX), which monetizes oral platforms through high-margin licensing, this indicator reflects market expectations for future revenue streams. The expected P/S valuation is calculated as the ratio of current market capitalization to projected sales volume, where an upward trend in the line signals a rising premium for technological superiority, while a decline indicates a devaluation of the business.
Key competitors
Forward P/S Multiple HLN (Haleon)|Kenvue Inc (KVUE) - Market Cap to Future Revenue Ratio|VRNA - Price-to-Projected Revenue Ratio|MENS (Jyong Bio) - Market Cap to Projected Revenue|LGND (Ligand Pharmaceuticals) - Forward Price-to-Revenue Multiple|AMRX: Price to Expected Revenue Ratio|PRGO (Perrigo) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Alvotech S.A. ALVO|Price-to-Projected Revenue Ratio Liquidia Technologies (LQDA)|GLPG (Galapagos Corp) - Forward Price to Sales|Forward P/S Multiple ANIP (ANI Pharmaceuticals)|Forward P/S Multiple mannkindcorp.com MNKD|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira Pharmaceuticals)|SPRY: Forward P/S Multiple|TBPH (Theravance Corp) - Price-to-Projected Revenue Ratio|AQST (Aquestive Therapeutics) - Forward P/S Multiple|scPharma (SCPH) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Tectonic Therapeutic, Inc. (TECX)|TNXP - Market Cap to Future Revenue Ratio|China SXT Pharmaceuticals, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|EXOZ: Price-to-Projected Revenue Ratio|ORMP (oramed.com) - Forward Price-to-Revenue Multiple|HYFT: Price to Expected Revenue Ratio|ABVC (ABVC BioPharma Inc) - Forward P/S Multiple|Market Cap to Projected Revenue CPIX (Cumberland Corp)|Forward Price-to-Revenue Multiple QNTM (Quantum BioPharma Ltd)|Market Cap to Expected Sales Ratio fibrogen.com|Forward P/S Multiple TELO (Telomir Pharmaceuticals, Inc.)|Rani Therapeutics Holdings (RANI) - Market Cap to Future Revenue Ratio|SNYR - Price-to-Projected Revenue Ratio|RLYB (Rallybio Corporation) - Market Cap to Projected Revenue|LEXX (lexariabioscience.com) - Forward Price-to-Revenue Multiple|PULM: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple PTHL|Market Cap to Projected Revenue APM (Aptorum)|Price-to-Projected Revenue Ratio Lyra Therapeutics, Inc (LYRA)|IBO: Future Price to Revenue|Forward P/S Multiple TNFA (TNF Pharmaceuticals, Inc.)|Forward Price to Sales YCBD|PainReform - Forward P/S Multiple|CYTO - Forward P/S Multiple|Lipella (LIPO) - Price-to-Projected Revenue Ratio|OptiNose Corp - Forward Price to Sales|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals|Forward Price-to-Revenue Multiple procapsgroup.com (PROC)|Forward P/S Multiple PTPI|Forward P/S Multiple Qilian International Holding Group (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales TFFP
